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Introduction: Magnesium exerts analgaesic effects in
several animal pain models, as well as in patients
affected by acute postoperative pain and neuropathic
chronic pain. There is no evidence that magnesium can
modulate pain in patients with peripheral arterial
occlusive disease (PAOD). We describe the protocol of
a single-centre randomised double-blind clinical trial
aimed at assessing the efficacy of oral magnesium
supplementation in controlling severe pain in patients
with advanced PAOD.
Methods and analysis: Adult patients affected by
PAOD at stages III and IV of Lèriche-Fontaine
classification, who are opioid-naïve, and who have
been admitted to our Acute Pain Service for intractable
pain, will be eligible. Patients will be randomised to the
control group, treated with standard therapy
(oxycodone and pregabalin) plus placebo for 2 weeks,
or to the experimental group (standard therapy plus
magnesium oxide). Patients will be evaluated on days
0, 2, 4, 6, 8, 12 and 14; the following information will
being collected: daily oxycodone dose; average and
maximum pain (Numerical Rating Scale); pain relief
(Pain Relief Scale); characteristics of the pain
(Neuropathic Pain Scale); impact of pain on the
patient’s daily activities (Brief Pain Inventory). The
primary outcome will be oxycodone dosage needed to
achieve satisfactory analgaesia on day 14. Secondary
outcomes will be pain relief on day 2, time needed to
achieve satisfactory analgaesia and time needed to
achieve a pain reduction of 50%. A sample size
calculation was performed for the primary outcome,
which estimated a required sample size of 150 patients
(75 per group).
Ethics and dissemination: Ethical approval of the
study protocol has been obtained from Comitato
Etico Provinciale di Brescia, Brescia, Italy. Trial
results will be disseminated through scientific
journal manuscripts and scientific conference
presentations.
Trial registration number: NCT02455726.
INTRODUCTION
Background
Magnesium is a physiological voltage-
dependent blocker of N-methyl-D-aspartate
(NMDA)-coupled channels.1 2 Magnesium
ions can inﬂuence inﬂammatory pain and
neuropathic pain through several different
mechanisms,3–6 including a decrease in
NMDA receptor activity in the central
nervous system by blocking the receptor-
coupled calcium channel, a reduction in
activity of other presynaptic and postsynaptic
calcium channels, a reduction of substance p
synthesis, a potentiation of the action of mor-
phine in the presynaptic area of dorsal horn,
a modulation of release and action of the
glutamate, the substance p and the calcito-
nine gene-related peptide (CGRP) in the
spinal cord, and a reduction in thromboxane
A2, and other proinﬂammatory eicosanoids
and cytokines outside the central nervous
system.7 8
Magnesium has been shown to exert an
analgaesic effect both in animals, in particu-
lar in rats with diabetic peripheral
Strengths and limitations of this study
▪ There are no randomised clinical trials on the
use of magnesium to control pain in peripheral
arterial occlusive disease.
▪ Magnesium oxide is a low-cost oral drug with
high safety profile. Its adoption would also be
affordable in low-income and middle-income
countries for use in polypharmacological pain
therapy.
▪ As a single-centre trial, generalisability of results
may be limited, and will require replication at
other centres with different patient populations.
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neuropathy,9–11 drug-induced neuropathy12 and spinal
nerve ligation,11 13 as well as in humans with a variety of
acute and chronic conditions. There is evidence for a
positive interactive effect on pain using magnesium with
narcotic analgaesics and intravenous general anaes-
thetics,14–16 local anaesthetics15 and antidepressants.17 18
In humans, magnesium can be considered as an
effective adjunct for postoperative analgaesia in the
setting of conventional opioid-based therapy: periopera-
tive magnesium can provide a clinically important reduc-
tion in opioid consumption in the ﬁrst 24 h
postoperatively, without any reported serious adverse
effects.19 Magnesium bolus followed by continuous intra-
venous infusion leads to signiﬁcant reduction in both
intraoperative dosage of propofol and atracurium, and
postoperative morphine consumption.20 Magnesium
sulfate during total intravenous anaesthesia improves the
quality of postoperative analgaesia21 22 and prevents
remifentanil-induced hyperalgaesia.23 Magnesium
enhances the analgaesic effect of metamizol on post-
tonsillectomy pain24 and, if administered preoperatively,
it is effective in reducing the incidence and severity of
postoperative sore throat in the immediate postoperative
period.25
Magnesium supplementation is effective in neuro-
pathic pain,26–29 and can reduce pain intensity and
improve lumbar spine mobility in patients with refractory
chronic low back pain with a neuropathic component.30
However, ﬁndings on the efﬁcacy of magnesium on
pain reduction are not consistent across studies.31
Pickering et al32 showed that magnesium alone did not
improve neuropathic pain compared to placebo. Felsby
et al33 failed to demonstrate any reduction in pain fol-
lowing magnesium administration in patients with
chronic neuropathic pain. Mikkelsen et al34 tested the
effect of magnesium sulfate administration on hyperal-
gaesia following heat/capsaicin stimulation in healthy
volunteers and found no evidence of beneﬁt.
In patients with advanced-stage peripheral arterial
occlusive disease (PAOD), pain is severe and is a major
factor in limiting patients’ activities in daily life. The
characteristics of ischaemic pain change from nocicep-
tive pain in patients with intermittent claudication to
predominantly neuropathic pain in patients with critical
limb ischaemia.35 Oral magnesium supplementation
improves endothelial function in patients with systemic
arterial disease and improves cardiac exercise tolerance
and quality of life in patients with coronary artery
disease.36 Magnesium supplementation has therefore a
preventive role in atherosclerosis, and may exert an
analgaesic effect on vascular pain.
There are no randomised controlled studies evaluat-
ing the efﬁcacy of oral magnesium as a supplemental
treatment in patients with PAOD-related pain.
Objectives and hypotheses
Our aim is to study the effect of oral magnesium supple-
mentation in opioid-naïve patients with PAOD with stage
III or IV disease according to Lèriche-Fontaine classiﬁca-
tion,37 and severe acute pain.
The hypothesis is that oral magnesium can contribute
to achieving a good level of analgaesia while reducing
opioid dosage in an elderly population affected by
atherosclerosis.
METHODS
Trial design and study setting
This is a single-centre randomised double-blind clinical
trial conducted at the Department of Anaesthesia,
Critical Care Medicine and Emergency and the
Department of General Surgery of the Spedali Civili, a
large, regional hospital afﬁliated with the University of
Brescia and serving a population of 1 million people in
the north-east of Italy. All consecutive patients with
PAOD attending the inpatient Acute Pain Service will be
evaluated by the anaesthesiologist in charge and invited
to take part in the study, if eligible.
The protocol adheres to the SPIRIT standards
(http://www.spirit-statement.org/).
Participants
The study will recruit all adult patients (aged 18 years or
above) presenting with pain due to PAOD at stages III
and IV according to the Lèriche-Fontaine classiﬁcation,
and with no treatment with opioids and magnesium at
the time of recruitment.
Patients will be excluded if they present any of the
following conditions: renal failure (serum creatinine
≥2.0 mg/dL); congestive heart failure (New York Heart
Association, NYHA >3); treatment with digoxin and/or
calcium-channel blockers; pre-existing neuromuscular
diseases; chronic diarrhoea; acute limb ischaemia suc-
cessfully treated with interventional angiography;
Fogarty embolectomy and/or surgical revascularisation.
Intervention, procedures and standard care
Patients will be evaluated using the Numeric Rating
Scale (NRS), the Pain Relief Scale (PRS), the
Neuropathic Pain Scale (NPS) and the Brief Pain
Inventory (BPI).
NRS is designed to evaluate average and maximum
pain intensity with a score of 0 indicating no pain and a
score of 10 indicating the worst pain, while PRS38 evalu-
ates pain relief, ranging from 0% indicating no pain
relief to 100% indicating complete pain relief. At short-
term evaluation, the assessment of pain relief is more
appropriate than assessment of pain intensity, because
all patients have the same baseline score (0 pain relief),
whereas pain intensity scores at baseline can be differ-
ent. NPS39–42 describes the characteristics of neuropathic
pain and consists of 10 items characterising patient’s
pain in terms of reactions to light touch or clothing.
Finally, BPI41 42 is designed to assess the impact of
pain on patients’ activities in daily life on admission (day
0) and on day 14.
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Patients with PAOD at stages III and IV have severe
pain at rest and the use of opioids represents a standard
of care. Therefore, magnesium will be used as supple-
mental treatment. Eligible patients will be randomised
to standard therapy plus magnesium oxide 300 mg twice
a day or standard therapy with placebo, consisting of
fructose 10 g. We will use an oral soluble preparation of
magnesium (Mag Orosolubile, Sanoﬁ Aventis), one dose
of which contains magnesium oxide 300 mg, citric acid,
monosodium citrate, sorbitol, aspartame, sodium cycla-
mate and lemon ﬂavouring.
Standard therapy consists of an oral administration of
oxycodone 5 mg and pregabalin 25 mg/day for 2 weeks.
Patients will receive oxycodone hydrochloride 5 mg
(Oxycontin, Mundipharma Pharmaceutical) at 8:00 and
pregabalin 25 mg (Lyrica, Pﬁzer Italia Srl) at 20:00.
Starting by day 2, the opioid dose will be titrated every
48 h in order to reach the maximum therapeutic goal
and to minimise side effects. At each clinical evaluation
on day 2, 4, 6, 8, 12 and 14, the dose of the oxycodone
will be increased by 5–10 mg, according to patient’s age,
body weight, and renal and liver function, to reach a
NRS≤4. A rescue dose of paracetamol 1 g will be pro-
vided if needed (maximum dose 3 g/day).
Outcome measure
Primary outcome measure
The primary outcome is the daily oxycodone dosage
needed to achieve ‘satisfactory analgaesia’, deﬁned as
NRS≤4 after 14 days of therapy.
Secondary outcome measures
The secondary outcomes are: level of pain relief on day
2 measured using PRS; time needed to achieve satisfac-
tory analgaesia (NRS≤4); time needed to achieve a
reduction of pain of 50% (PRS≥50%).
Randomisation and blinding
Participants will be randomly assigned to either the
experimental or the control group with a 1:1 allocation
ratio using a computer-generated randomisation sched-
ule based on permuted blocks. To ensure allocation con-
cealment, the block size will not be disclosed and
allocation will be assigned using sequentially numbered,
opaque, sealed envelopes. Trial participants, care provi-
ders and data collectors, including outcome assessors
and data analysts, will be blinded to group allocation.
Magnesium and placebo are white powder, indistinguish-
able to the eye and to the touch. Oral magnesium and
placebo will be prepared by two physicians in the Acute
Pain Service using identical test tubes. In particular, the
contents of each magnesium sachet will be poured into
a small plastic test tube, and the same will be done for
the 10 g of fructose (1 measuring spoon). The two physi-
cians will monitor the blinding procedure, but they will




A sample size calculation was performed for the primary
outcome, that is, oxycodone dosage needed to achieve a
NRS≤4 on day 14. We considered a mean oxycodone
dose of 20.25 mg (SD 10 mg) on day 14 in the control
group, based on data from 270 patients with advanced
PAOD treated by our Acute Pain Service in the period
2012–2014. For a signiﬁcance threshold of 5% (p<0.05,
two-sided test), 116 patients (58 per group) would be
needed to achieve 90% power to detect a minimum
reduction in oxycodone dose of 30% in the experimen-
tal compared with the control group (ie, mean oxy-
codone dose of 14.18 mg in the experimental group).
The target sample size was increased to 150 patients (75
per group) to account for a possible dropout rate of
approximately 20%. The sample size of 150 patients
allows for an 80% power to detect an increase in pain
relief on day 2 (secondary outcome) from 10% in the
control group to a minimum of 30% in the experimen-
tal group.
Statistical analyses
Descriptive statistics will be used to summarise patients’
characteristics and baseline outcome data in the two
treatment groups. Differences between experimental
and control group in daily oxycodone dose on day 14
(primary outcome) and pain relief on day 2 (secondary
outcome) will be analysed using a t test if the data (ori-
ginal or transformed) are normally distributed, and with
a Mann-Whitney U test if normality cannot be achieved.
For the two time-to-event secondary outcomes (time
needed to achieve satisfactory analgaesia and 50% pain
reduction), differences between the two groups will be
tested using a log-rank test. In the case of imbalance
between the two groups in baseline characteristics
strongly associated with the outcome (confounding by
chance), sensitivity analyses with adjustment for these
covariates will be performed, using multiple linear
regression and Cox regression. Analyses will be per-
formed according to the intention to treat principle.
All tests will be two tailed, and p<0.05 will be consid-
ered as signiﬁcant. For binary outcomes, ORs will be esti-
mated with their 95% CI. Analyses will be performed




Figure 1 shows the study ﬂow reported according to the
Consolidated Standards of Reporting Trials
(CONSORT).
Recruitment time frame
Patients meeting the inclusion criteria will be invited to
participate, with written informed consent obtained
before randomisation. Patients will be randomised as
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soon as they need the ﬁrst dose of opioid for pain man-
agement, as assessed by the Acute Pain Service team,
and the treatment will last 14 days. Patients discharged
from the hospital before day 14 will be discharged with
the pain therapy (including magnesium or placebo) and
will be assessed as outpatients in our ambulatory pain
clinic at the expected intervals.
Data collection
The following patient characteristics will be recorded at
baseline (table 1): age, gender, body weight and height,
lifestyle habits (including smoking) and comorbidities
(diabetes, cardiac and cerebrovascular events, and
cancer, as well as Charlson Comorbidity Index43 44).
The following data on pain will be recorded on day 0
(baseline): patient’s perceived average and maximum
pain (NRS); pain characteristics (NPS); impact of pain
on patient’s daily activities (BPI) (table 1).
The following data on pain and treatment will be
recorded on day 2, 4, 6, 8, 12 and 14: daily oxycodone
dose; number of paracetamol rescue doses requested
and administered; patient’s perceived average and
maximum pain (NRS); pain relief (PRS); pain character-
istics (NPS); gastrointestinal side effects, including diar-
rhoea/constipation. Impact of pain on patient’s daily
activities will be recorded on day 14 (table 1).
DISCUSSION
Interpretation, limitations and generalisability
Opioid analgaesics are risky drugs in patients with
chronic non-cancer pain; they can be effective in treat-
ing a variety of chronic pain conditions, but their use
can be potentially accompanied by side effects and com-
plications: not only abuse, addiction and tolerance, but
also sedation, dizziness, drowsiness, constipation, nausea,
vomiting and delayed gastric emptying, etc.45
These side effects are very crippling for old patients,
who may lose their self-reliance. Magnesium may aid in
maximising the effectiveness of opioids while reducing
their dose, and thus the severity of side effects.
In addition to its NMDA-blocking properties, magne-
sium has vasodilatory effects, improves endothelial func-
tion36 and exerts antidepressant action.11 12 If proved
effective, the analgaesic effect might be due to a com-
bined mechanism. Magnesium has a high safety proﬁle,
Figure 1 Study flow will be
reported according to the
Consolidated Standards of
Reporting Trials (CONSORT).
Table 1 Patient’s characteristics and data collection
Data collection
Days








Oxycodone dose, mg x x x x x x
Rescue dose paracetamol x x x x x x
Average pain, NRS x x x x x x x
Maximum pain, NRS x x x x x x x
Pain relief x x x x x x
Neuropathic Pain Scale x x x x x x x
Brief Pain Inventory x x
Side effects x x x x x x
NRS, Numeric Rating Scale.
4 Venturini MA, et al. BMJ Open 2015;5:e009137. doi:10.1136/bmjopen-2015-009137
Open Access
lacks serious side effects and is a low cost drug. The
most frequent and expected side effect is mild diar-
rhoea, which could be helpful in counteracting
opioid-related constipation.
As a single-centre RCT, demonstration of the analgae-
sic efﬁcacy of magnesium supplementation would
require replication in other centres before magnesium is
adopted as a standard of treatment in advanced-stage
patients with PAOD with severe pain; in particular, gen-
eralisability of results to patients with PAOD with less
severe disease or to other conditions characterised by
acute neuropathic pain would require further evidence.
ETHICS AND DISSEMINATION
Detailed written information will be provided to the
patients about the study protocol, the purpose of
research and the safety of magnesium treatment.
Written informed consent will be requested from all
patients before randomisation. All investigations will be
conducted according to the principles expressed in the
Declaration of Helsinki.
All study-related information will be stored securely at
the study site; sensible information will be stored in
locked ﬁle cabinets in areas with limited access. All
records that contain names or other personal identiﬁers
will be stored separately from study records identiﬁed by
code number. Participants’ study information will not be
released outside of the study without the written permis-
sion of the participant.
Trial results will be disseminated through scientiﬁc
journal manuscripts and scientiﬁc conference
presentations.
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